Close
Help




JOURNAL

Biomarker Insights

Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD

Submit a Paper


Biomarker Insights 2015:10 63-73

Original Research

Published on 16 Aug 2015

DOI: 10.4137/BMI.S28209


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarker Insights

Abstract

Interstitial lung disease (ILD) is frequently associated with collagen disease. It is then designated as collagen vascular disease-associated ILD (CVD-ILD), and influences patients' prognosis. The prognosis of acute-onset diffuse ILD (AoDILD) occurring in patients with collagen disease is quite poor. Here, we report our investigation of auto-antibody (Ab) profiles to determine whether they may be useful in diagnosing CVD-ILD or AoDILD in collagen disease. Auto-Ab profiles were analyzed using the Lambda Array Beads Multi-Analyte System, granulocyte immunofluorescence test, ProtoArray Human Protein Microarray, AlphaScreen assay, and glutathione S-transferase capture enzyme-linked immunosorbent assay in 34 patients with rheumatoid arthritis (RA) with or without CVD-ILD and in 15 patients with collagen disease with AoDILD. The average anti-major histocompatibility complex class I-related chain A (MICA) Ab levels were higher in RA patients with CVD-ILD than in those without (P = 0.0013). The ratio of the average anti-MICA Ab level to the average anti-human leukocyte antigen class I Ab level (ie, MICA/Class I) was significantly higher in RA patients with CVD-ILD compared with those without (P = 4.47 × 10⁻⁵). To the best of our knowledge, this is the first report of auto-Ab profiles in CVD-ILD. The MICA/Class I ratio could be a better marker for diagnosing CVD-ILD than KL-6 (Krebs von den lungen-6).



Downloads

PDF  (899.62 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

Supplementary Files 1  (328.56 KB ZIP FORMAT)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing


What Your Colleagues Say About Biomarker Insights
testimonial_image
I have had a great experience with submitting my cancer prognosis study to Biomarker Insights. The comments from reviewers and associate editor are high quality and insightful. Congratulations and keep up the good work.
Dr Yi Hong Zhou (University of California, Irvine, CA, USA)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube